Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals.
about
Blood-Based Proteomic Biomarkers of Alzheimer's Disease PathologyImportance of Apolipoprotein A-I in Multiple SclerosisGenomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease.Circulating biomarkers that predict incident dementia.Complement-Mediated Regulation of Apolipoprotein E in Cultured Human RPE Cells.The potential applications of Apolipoprotein E in personalized medicineDeveloping novel blood-based biomarkers for Alzheimer's diseaseHDL and cognition in neurodegenerative disorders.Quantitative proteomics of delirium cerebrospinal fluid.Investigating the genetics of hippocampal volume in older adults without dementia.Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsPlasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men.Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults.Blood protein predictors of brain amyloid for enrichment in clinical trials?Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke.Clusterin/Apolipoprotein J immunoreactivity is associated with white matter damage in cerebral small vessel diseasesThe human secretome atlas initiative: implications in health and disease conditions.Age-dependent effect of Alzheimer's risk variant of CLU on EEG alpha rhythm in non-demented adults.Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer DiseasePeripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism.Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies.Proteomic Analyses for the Global S-Nitrosylated Proteins in the Brain Tissues of Different Human Prion Diseases.Is intraindividual reaction time variability an independent cognitive predictor of mortality in old age? Findings from the Sydney Memory and Ageing Study.Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.Sydney Memory and Ageing Study: an epidemiological cohort study of brain ageing and dementia.Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease.Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.Genetic variants associated with risk of Alzheimer's disease contribute to cognitive change in midlife: The Atherosclerosis Risk in Communities Study.Syphilitic dementia and lipid metabolism.Alcohol Consumption and Incident Dementia: Evidence from the Sydney Memory and Ageing Study.Cerebrospinal Fluid Apolipoprotein E Levels in Delirium.Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes.Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease.Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.
P2860
Q26774743-16E10295-0437-4607-8489-348A15164A3FQ26774792-0FC98A3F-6EED-4705-B2E3-A0CAB3462C3FQ33637672-4C0A42D4-6322-4B03-8919-BCF495B22B1AQ33752058-473E66EA-EDB3-45FE-9612-66F8A13822EEQ33828385-B48EEB5B-D05F-42B3-8A4E-5342C5E56F13Q33858831-764DC505-A587-4C2E-878E-4A3134A32276Q34394080-FB58DB7C-E5CA-4C47-9F8F-8916C2DE5E5BQ34614842-8B7F46BA-404F-489F-9A29-9BE18CF54676Q34657974-DFF8F72B-1D6B-4E2B-83E2-D40257A8D6C4Q35019172-D7C22A22-33C3-46B8-813F-6B8EDB0606A8Q35071184-374CF740-EDB2-4223-B628-434C3CC7509DQ35099780-D5823EC8-C49E-45D0-9C17-7FC7ED47B500Q36165011-7957CFF2-88F9-4238-8B83-5F6423AAE573Q36256076-8DEA584E-3AE2-4FFB-BA21-A4B3291E389CQ36349870-3156E710-A3AA-4AC4-85F8-2A6D69AEC1BCQ36409186-0658E971-1F4C-426A-8E61-3D0449357FF8Q36748126-D715EBA9-9B98-4ABE-9959-BD3BBA74AFE5Q36926754-5DCDEB22-D8B1-4EC3-98F1-3FF2FF8395CAQ37105427-93A53814-24F4-42C6-ADA5-2C19FF77AB01Q37105606-A9F56CCD-EB37-4DA0-BE27-F21CECBFFED1Q37126245-4F6A1817-03BC-4A96-9643-33F9E4BB03A0Q37389105-16B1CD51-024B-4D4B-8B58-0131D432CD22Q37504001-37AB5EC6-A4E3-428B-B0CF-58D6359E1C37Q37559815-F331268E-996B-4D23-80B1-89A40C75073FQ37615967-A7166F94-51CA-4163-98A7-F8F157492C5BQ38287482-2C68E980-47D5-4933-B104-CB92569F0B9EQ38403381-3BEB8C6E-AB10-444E-8121-5AE13CA00BECQ38632264-2D945A87-DF00-4BEA-BEAB-6061633DB337Q39230272-4D954D5D-BF4E-4F43-A5E2-06FAC0854342Q39272772-555E5C20-8149-4F32-A874-7F8878B79FE1Q39307470-6E9889AD-274E-413A-B400-842B98E02996Q40401981-4DC53C23-1866-45B5-8BDE-A1698E3FE896Q40514964-C9602087-D1E7-48DC-95FB-FC0F199964C8Q40613739-2544C975-71BD-481B-813F-473EFD968F3CQ40825010-851F64E1-AD9B-46CD-A133-BB34576CFE17Q41488020-76001B2A-3CE0-46D1-ACC7-8F8318A04A78Q42281478-6424AA73-7BFE-4AF2-8DC5-239DF98E3EA2Q42328283-7281E719-612E-4712-BDFF-D4A7C134CA9BQ45754969-B14850A3-2F84-4E72-8197-9D87AFC5E988Q47155881-C983903A-996A-44AC-ACA2-C882ABD0BDA6
P2860
Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@ast
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@en
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@nl
type
label
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@ast
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@en
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@nl
prefLabel
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@ast
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@en
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@nl
P2093
P2860
P1433
P1476
Plasma apolipoprotein levels a ...... y cohort of older individuals.
@en
P2093
Anne Poljak
Barbara Cameron
George A Smythe
John Crawford
Karen Mather
Nicole A Kochan
P2860
P304
P356
10.1371/JOURNAL.PONE.0034078
P407
P577
2012-06-11T00:00:00Z